Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Oct 7, 2013; 19(37): 6127-6130
Published online Oct 7, 2013. doi: 10.3748/wjg.v19.i37.6127
Published online Oct 7, 2013. doi: 10.3748/wjg.v19.i37.6127
Strategy for improving survival and reducing recurrence of HCV-related hepatocellular carcinoma
Toru Ishikawa, Department of Gastroenterology and Hepatology, Saiseikai Niigata Daini Hospital, Niigata 950-1104, Japan
Author contributions: Ishikawa T collected the materials and wrote the manuscript.
Correspondence to: Toru Ishikawa, MD, PhD, Department of Gastroenterology and Hepatology, Saiseikai Niigata Daini Hospital, 280-7 Teraji, Niigata 950-1104, Japan. toruishi@ngt.saiseikai.or.jp
Telephone: +81-25-2336161 Fax: +81-25-2338880
Received: June 2, 2013
Revised: August 2, 2013
Accepted: August 8, 2013
Published online: October 7, 2013
Processing time: 137 Days and 23.9 Hours
Revised: August 2, 2013
Accepted: August 8, 2013
Published online: October 7, 2013
Processing time: 137 Days and 23.9 Hours
Core Tip
Core tip: Recent advances in treatment modalities have improved the survival rate of patients with hepatocellular carcinoma (HCC). However, long-term outcomes of patients with HCC remain unsatisfactory because of the high incidence of distant intrahepatic recurrence, multicentric recurrence and low survival rates. In particular, hepatitis C virus-related hepatocellular carcinoma has a much higher recurrence rate than other cancers. In this article, we describe the prognosis of recurrent HCC and the therapeutic strategies for reducing recurrent HCC.